Linkage receives $2m boost for molecular Dx
This article was originally published in Clinica
Linkage Biosciences has secured $2m to help develop its line of molecular diagnostic tests after closing a series A financing round. The funding was led by Greenhouse Capital and James Fisher, a managing member of Fisher Capital. San Francisco, California-based Linkage said that the new capital would be used to further the development and marketing of its test for human leukocyte antigen (HLA) typing, used in organ transplantation to detect whether or not a body will reject foreign tissues. The company also said it was looking to develop a portfolio of diagnostics in other areas of transplantation.
You may also be interested in...
Alere’s professional diagnostics business helped the firm record overall revenue growth in the fourth quarter of 2010, offsetting a fall in influenza-based sales in North America.
Integra LifeSciences has gained exclusive worldwide rights from Stout Medical to develop and commercialise an expandable interbody fusion device.
Gen-Probe recently launched its Panther automated molecular diagnostics system in Europe with the aim of bringing another dimension to its product portfolio. Joseph Harvey met the firm’s CEO, Carl Hull, at the launch of the product in Frankfurt to find how high the firm has set its sights in the molecular diagnostics sector and how it is going to achieve its goals